Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970008 | 1.00 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2TSHRMAPK1TDP1 | |
| Isophthalic Acid SCHEMBL27639823 | 0.91 | KMT2A (0.55) | ALDH1A1SMN1; SMN2TSHRMAPK1TDP1 | |
| SCHEMBL12415404 | 0.88 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2KMT2ALMNAHTT | |
| SCHEMBL6272090 | 0.88 | KMT2A (0.64) | ALDH1A1SMN1; SMN2TSHRMAPK1TDP1 | |
| SCHEMBL1269684 | 0.86 | CYP3A4 (0.67) | ALDH1A1SMN1; SMN2MAPK1KMT2ALMNA | |
| SCHEMBL20488351 | 0.86 | KMT2A (0.55) | ALDH1A1SMN1; SMN2KMT2ALMNANPC1 | |
| SCHEMBL2183180 | 0.86 | POLB (0.68) | ALDH1A1SMN1; SMN2KMT2ALMNANPC1 | |
| SCHEMBL5069460 | 0.86 | POLB (0.68) | ALDH1A1SMN1; SMN2KMT2ALMNANPC1 | |
| SCHEMBL5781007 | 0.86 | POLB (0.68) | ALDH1A1SMN1; SMN2KMT2ALMNANPC1 | |
| SCHEMBL7617626 | 0.85 | TDP1 (0.57) | ALDH1A1SMN1; SMN2TSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104402791-A | Preparation method for nebracetam | UNIV HENAN NORMAL | 2015-03-11 | — | — | CN | claimed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024229447-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-111808007-B | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-4604401-A | QUINOLINE-CARBOXYLIC ACIDS | WARNER-LAMBERT COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| US-4578473-A | Process for quinoline-3-carboxylic acid antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| EP-0174077-A1 | -9-fluoro-6,7-dihydro-5-methyl-1-oxo-8-substituted-1H,5H, benzo(ij)-quinoziline-2-carboxylic acids; their derivatives; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-03-12 | — | — | EP | disclosed |
| EP-0172651-A1 | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0169710-A2 | 7-Substituted-6-fluoro-8-substituted-1,4-dihydro-1-methylamino-4-oxo-3-quinolinecarboxylic acids; 7-substituted-6-fluoro-1,4-dihydro-1-methylamino-4-oxo-3-naphthyridine carboxylic acids; derivatives thereof; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-01-29 | — | — | EP | disclosed |
| US-4550103-A | Antibacterial 1-oxo-benzoquinolizine-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
| US-4550104-A | Antibacterial thiazolo-quinolines and thiazolo-naphthyridines | WARNER-LAMBERT COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
| EP-0153163-A2 | 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0106489-A2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1984-04-25 | — | — | EP | disclosed |
| US-4071530-A | Pyrrolidones and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | ALDH1A1 2167/4885SMN1; SMN2 2918/4885TSHR 4209/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | ALDH1A1 2167/4885SMN1; SMN2 2918/4885TSHR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.